Citations

Clear

1727 citation(s) found for "Fu, Alan".

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance)
Lenz, Heinz‐Josef , Höchster, Howard S. , Niedzwiecki, Donna , Goldberg, Richard M. , Blanke, Charles D. , Qu, Xueping , Wirapati, Pratyaksha , Innocenti, Federico , Kabbarah, Omar , Niedzwiecki, Donna , Ou, Fang‐Shu , Venook, Alan P. , Mayer, Robert J. , Bertagnolli, Monica M. , Zemla, Tyler , Tejpar, Sabine

Mayo Clinic

Journal of Clinical Oncology | May 1, 2019 | Volume: 37 | Issue: 22 | Pages: 1876-1885

10.1200/jco.18.02258 | PMID 31042420 Get It

PURPOSETo determine the predictive and prognostic value of the consensus molecular subtypes (CMSs) of colorectal cancer (CRC) that represent a merging of gene expression–based features largely in primary tumors from six independent classification systems and provide a framework for capturing the intrinsic heterogeneity of CRC in patients enrolled in CALGB/SWOG 80405.PATIENTS AND METHODSCALGB/SWOG 80405 is a phase III trial that compared the addition of bevacizumab or cetuximab to infusional fluorouracil, leucovorin, and oxaliplatin or fluorouracil, leucovorin, and irinotecan as first-line treatment of advanced CRC. We characterized the CMS classification using a novel NanoString gene expression panel on primary CRCs from 581 patients enrolled in this study to assess the prognostic and predictive value of CMSs in these patients.RESULTSThe CMSs are highly prognostic for overall survival (OS; P < .001) and progression-free survival (PFS; P < .001). Furthermore, CMSs were predictive for both OS ( P for interaction < .001) and PFS ( P for interaction = .0032). In the CMS1 cohort, patients treated with bevacizumab had a significantly longer OS than those treated with cetuximab ( P < .001). In the CMS2 cohort, patients treated with cetuximab had a significantly longer OS than patients treated with bevacizumab ( P = .0046).CONCLUSIONThese findings highlight the possible clinical utility of CMSs and suggests that refinement of the CMS classification may provide a path toward identifying patients with metastatic CRC who are most likely to benefit from specific targeted therapy as part of the initial treatment.
Comparison of Patient‐Reported Care Satisfaction, Quality of Warfarin Therapy, and Outcomes of Atrial Fibrillation: Findings From the ORBIT‐AF Registry
Perino, Alexander C., Shrader, Peter, Turakhia, Mintu P., Ansell, Jack E., Gersh, Bernard J., Fonarow, Gregg C., Go, Alan S., Kaiser, Daniel W., Hylek, Elaine M., Kowey, Peter R., Singer, Daniel E., Thomas, Laine, Steinberg, Benjamin A., Peterson, Eric D., Piccini, Jonathan P., Mahaffey, Kenneth W., Mahaffey, Kenneth W. , Turakhia, Mintu P. , Turakhia, Mintu P , Perino, Alexander C., Shrader, Peter, Ansell, Jack E., Gersh, Bernard J., Fonarow, Gregg C., Go, Alan S., Kaiser, Daniel W., Hylek, Elaine M., Kowey, Peter R., Singer, Daniel E., Thomas, Laine, Steinberg, Benjamin A., Peterson, Eric D., Piccini, Jonathan P.

Mayo Clinic

Journal of the American Heart Association | April 26, 2019 | Volume: 8 | Issue: 9 | Pages: No page available

10.1161/jaha.118.011205 | PMID 31023126 Get It

Background Patient satisfaction with therapy is an important metric of care quality and has been associated with greater medication persistence. We evaluated the association of patient satisfaction with warfarin therapy to other metrics of anticoagulation care quality and clinical outcomes among patients with atrial fibrillation ( AF ). Methods and Results Using data from the ORBIT ‐ AF (Outcomes Registry for Better Informed Treatment of Atrial Fibrillation) registry, patients were identified with AF who were taking warfarin and had completed an Anti‐Clot Treatment Scale ( ACTS ) questionnaire, a validated metric of patient‐reported burden and benefit of oral anticoagulation. Multivariate regressions were used to determine association of ACTS burden and benefit scores with time in therapeutic international normalized ratio range ( TTR ; both ≥75% and ≥60%), warfarin discontinuation, and clinical outcomes (death, stroke, major bleed, and all‐cause hospitalization). Among 1514 patients with AF on warfarin therapy (75±10 years; 42% women; CHA 2 DS 2 ‐ VAS c 3.9±1.7), those most burdened with warfarin therapy were younger and more likely to be women, have paroxysmal AF , and to be treated with antiarrhythmic drugs. After adjustment for covariates, ACTS burden scores were independent of TTR ( TTR ≥75%: odds ratio, 1.01 [95% CI , 0.99–1.03]; TTR ≥60%: odds ratio, 1.01 [95% CI , 0.98–1.05]), warfarin discontinuation (odds ratio, 0.99; 95% CI , 0.97–1.01), or clinical outcomes. ACTS benefit scores were also not associated with TTR , warfarin discontinuation, or clinical outcomes. Conclusions In a large registry of patients with AF taking warfarin, ACTS scores provided independent information beyond other traditional metrics of oral anticoagulation care quality and identified patient groups at high risk for dissatisfaction with warfarin therapy.
Multiplatform biomarker analysis on non-sun exposed mucosal melanoma.
Arguello, David, Millis, Sherri Z. , Bender, Ryan , Gatalica, Zoran , González, René , Bryce, Alan H. , Reddy, Sandeep K.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: 9042-9042

10.1200/jco.2015.33.15_suppl.9042 Get It

Early change in lactate dehydrogenase is marker of response to PD-1/PDL1 inhibitors.
Shreders, Amanda , Johnson, Douglas B. , Peng, Chengwei , Dronca, Roxana , Kottschade, Lisa A. , Sosman, Jeffrey A. , Joseph, Richard W. , Puzanov, Igor , Bryce, Alan H. , Markovic, Svetomir N.

Mayo Clinic

Journal of Clinical Oncology | April 19, 2019 | Volume: 33 | Issue: 15_suppl | Pages: e20045-e20045

10.1200/jco.2015.33.15_suppl.e20045 Get It

Comparing the incidence of ventricular arrhythmias during epicardial ablation in swine versus canine models
Caluori, Guido , Wojtaszczyk, Adam , Yasin, Omar , Pešl, Martin , Wolf, Jiří , Bělašková, Silvie , Crha, Michal, Sugrue, Alan , Vaidya, Vaibhav R. , Naksuk, Niyada , Killu, Ammar M. , Padmanabhan, Deepak , Asirvatham, Samuel J. , Stárek, Zdeněk , DeSimone, Christopher V , Killu, Ammar M , Stárek, Zdeněk , Asirvatham, Samuel J , DeSimone, Christopher V.

Mayo Clinic

Pacing and Clinical Electrophysiology | April 16, 2019 | Volume: 42 | Issue: 7 | Pages: 862-867

10.1111/pace.13698 | PMID 30989679 Get It

Abstract Background Choosing the appropriate animal model for development of novel technologies requires an understanding of anatomy and physiology of these different models. There are little data about the characteristics of different animal models for the study of technologies used for epicardial ablation. We aimed to compare the incidence of ventricular arrhythmias during epicardial radiofrequency ablation between swine and canine models using novel epicardial ablation catheters. Methods We conducted a retrospective study using data obtained from epicardial ablation experiments performed on swine ( Sus Scrofa ) and canine ( Canis familiaris ) models. We compared the incidence of ventricular arrhythmias during ablation between swine and canine using multivariate regression analysis. Six swine and six canine animals underwent successful epicardial radiofrequency ablation. A total of 103 ablation applications were recorded. Results Ventricular arrhythmias requiring cardioversion occurred in 13.11% of radiofrequency ablation applications in swine and 9.75% in canine (relative risk: 117.6%, 95% confidence interval [CI]: 83.97‐164.69, animal‐based odds ratio [OR]: .55, 95% CI: .23‐61.33; P = .184). When adjusting for application position, duration of ablation and power, the odds of developing potentially lethal ventricular arrhythmia in swine increased significantly compared to canine (OR: 3.60, 95% CI: 1.35‐9.55; P = .010). Conclusions The swine myocardium is more susceptible to developing ventricular arrhythmias compared to canine model during epicardial ablation. This issue should be carefully considered in future studies.
Guidelines Insights: Hepatobiliary Cancers, Version 2.2019
Benson, Al B. , D’Angelica, Michael I., Abbott, Daniel E. , Anaya, Daniel A. , Are, Chandrakanth , Brown, Daniel B. , Cloyd, Jordan M. , Covey, Anne M. , Iyer, Renuka , Jacob, Rojymon , Karachristos, Andreas , Kelley, Robin Kate , Kim, Robin D. , Palta, Manisha , Park, James O. , Sahai, Vaibhav , Schefter, Tracey E., Singh, Gagandeep , Sohal, Davendra , Stein, Stacey , Tian, Guo , Hammond, Lydia J., Darlow, Susan, Abrams, Thomas A. , Alberts, Steven R. , Anders, Robert A. , Chang, Daniel T. , Hawkins, William G , Sicklick, Jason Keith , Tian, G. Gary, Vauthey, Jean‐Nicolas , Venook, Alan P. , Sahai, Vaibhav

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 8, 2019 | Volume: 17 | Issue: 4 | Pages: 302-310

10.6004/jnccn.2019.0019 | PMID 30959462 Get It

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel’s discussion and updated recommendations regarding systemic therapy for first-line and subsequent-line treatment of patients with hepatocellular carcinoma.
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Evgin, Laura , Kottke, Timothy, Thompson, Jill , Molan, Amy M. , Driscoll, Christopher B. , Schuelke, Matthew , Shim, Kevin G. , Wongthida, Phonphimon , Ilett, Elizabeth J. , Smith, Karen Kaluza, Pulido, José S. , Pandha, Hardev , Selby, Peter J. , Harrington, Kevin J. , Melcher, Alan , Vile, Richard G. , Huff, Amanda L. , Shim, Kevin G , Ilett, Elizabeth J , Melcher, Alan A , Harrington, Kevin , Driscoll, Christopher , Harris, Reuben S. , Coffey, Matt C.

Mayo Clinic

Cancer Immunology Research | April 2, 2019 | Volume: 7 | Issue: 5 | Pages: 828-840

10.1158/2326-6066.cir-18-0013 | PMID 30940643 Get It

Abstract Antitumor T-cell responses raised by first-line therapies such as chemotherapy, radiation, tumor cell vaccines, and viroimmunotherapy tend to be weak, both quantitatively (low frequency) and qualitatively (low affinity). We show here that T cells that recognize tumor-associated antigens can directly kill tumor cells if used at high effector-to-target ratios. However, when these tumor-reactive T cells were present at suboptimal ratios, direct T-cell–mediated tumor cell killing was reduced and the ability of tumor cells to evolve away from a coapplied therapy (oncolytic or suicide gene therapy) was promoted. This T-cell–mediated increase in therapeutic resistance was associated with C to T transition mutations that are characteristic of APOBEC3 cytosine deaminase activity and was induced through a TNFα and protein kinase C–dependent pathway. Short hairpin RNA inhibition of endogenous APOBEC3 reduced rates of tumor escape from oncolytic virus or suicide gene therapy to those seen in the absence of antitumor T-cell coculture. Conversely, overexpression of human APOBEC3B in tumor cells enhanced escape from suicide gene therapy and oncolytic virus therapy both in vitro and in vivo. Our data suggest that weak affinity or low frequency T-cell responses against tumor antigens may contribute to the ability of tumor cells to evolve away from first-line therapies. We conclude that immunotherapies need to be optimized as early as possible so that, if they do not kill the tumor completely, they do not promote treatment resistance.
Medicare Reimbursement for General Surgery Procedures
Haglin, Jack M. , Eltorai, Adam E. M. , Richter, Kent R. , Jogerst, Kristen, Jogerst, Kristen M. , Daniels, Alan H.

Mayo Clinic

Annals of Surgery | March 28, 2019 | Volume: 271 | Issue: 1 | Pages: 17-22

10.1097/sla.0000000000003289 | PMID 30921048 Get It

Objective: The purpose of this study is to evaluate monetary trends from 2000 to 2018 in Medicare reimbursement rates for the most common general surgery procedures. Summary Background Data: A complete understanding of financial trends in general surgery in the United States is lacking. As such, an evaluation of trends in reimbursement rates in general surgery is important for defining the specialty's current and future financial health. Methods: The Physician Fee Schedule Look-Up Tool from the Centers for Medicare and Medicaid Services was queried for each of the 20 top codes top in general surgery. The total raw percent change in Medicare reimbursement rate for each procedure from 2000 to 2018 was calculated and averaged. All data was corrected for inflation. Both average annual and total percentage change were calculated based on these adjusted trends. Compound annual growth rate was calculated using the adjusted data. Results: After adjusting all data for inflation, the reimbursement rate for all included procedures decreased by an average of 24.4% throughout the study period. During this time, the adjusted reimbursement rate decreased by an average of 1.4% each year with an average compound annual growth rate of −1.6%. Conclusion: After adjusting for inflation, Medicare reimbursement rates in general surgery have steadily decreased from 2000 to 2018. It is important that these trends are understood and considered by surgeons, healthcare administrators, and policy-makers in order to develop and implement agreeable models of reimbursement while ensuring access to quality general surgery care in the United States.
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, Derek, Biessels, Geert Jan , Braithwaite, Susan S., Draznin, Boris , Halter, Jeffrey B., McDonnell, Marie E. , Molitch, Mark E. , Murad, M. Hassan , Murad, M Hassan , McDonnell, Marie E , Biessels, Geert Jan , Casanueva, Felipe F. , Hirsch, Irl B. , Sinclair, Alan J.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | March 23, 2019 | Volume: 104 | Issue: 5 | Pages: 1520-1574

10.1210/jc.2019-00198 | PMID 30903688 Get It

Abstract Objective The objective is to formulate clinical practice guidelines for the treatment of diabetes in older adults. Conclusions Diabetes, particularly type 2, is becoming more prevalent in the general population, especially in individuals over the age of 65 years. The underlying pathophysiology of the disease in these patients is exacerbated by the direct effects of aging on metabolic regulation. Similarly, aging effects interact with diabetes to accelerate the progression of many common diabetes complications. Each section in this guideline covers all aspects of the etiology and available evidence, primarily from controlled trials, on therapeutic options and outcomes in this population. The goal is to give guidance to practicing health care providers that will benefit patients with diabetes (both type 1 and type 2), paying particular attention to avoiding unnecessary and/or harmful adverse effects.